A novel tetracycline-controlled transactivator–transrepressor system enables external control of oncolytic adenovirus replication
Open Access
- 18 August 2003
- journal article
- research article
- Published by Springer Nature in Gene Therapy
- Vol. 10 (19) , 1680-1690
- https://doi.org/10.1038/sj.gt.3302051
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- E1B-55K-Deleted Adenovirus Expressing E1A-13S by AFP-Enhancer/Promoter Is Capable of Highly Specific Replication in AFP-Producing Hepatocellular Carcinoma and Eradication of Established TumorMolecular Therapy, 2002
- Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacyNature Biotechnology, 2001
- Tissue-Specific, Tumor-Selective, Replication-Competent Adenovirus Vector for Cancer Gene TherapyJournal of Virology, 2001
- Target Gene Therapy for α-Fetoprotein-Producing Hepatocellular Carcinoma by E1B55k-Attenuated AdenovirusBiochemical and Biophysical Research Communications, 2001
- An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacyNature Medicine, 2000
- A Novel, Conditionally Replicative Adenovirus for the Treatment of Breast Cancer That Allows Controlled Replication of E1a-Deleted Adenoviral VectorsHuman Gene Therapy, 2000
- Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigenJournal of Clinical Investigation, 2000
- A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivoOncogene, 2000
- p53-dependent cell death/apoptosis is required for a productive adenovirus infectionNature Medicine, 1998
- An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor CellsScience, 1996